Table 1.
Study design for a randomised, blinded, vaccination-challenge study.
Fig 1.
Viraemia in pigs challenged with PRRSV.
a) Percentage of PCR positive pigs challenged with <1.5 log virulent PRRSV strain. b) Percentage of PCR positive pigs challenged with 2 log virulent PRRSV strain. c) Percentage of PCR positive pigs challenged with 3 log virulent PRRSV strain. d) Percentage of PCR positive pigs challenged with 4 log virulent PRRSV strain. MLV = modified-live virus; PCR = polymerase chain reaction; PRRS = porcine reproductive and respiratory syndrome; PRRSV = porcine reproductive and respiratory syndrome virus; TCID50 = 50% tissue culture infectious dose.
Table 2.
Mean number of days vaccinated, challenged pigs were pyrexic compared with non-vaccinated pigs post-challenge.
Fig 2.
Estimated number of days pyrexic by challenge dose based on model prediction.
Regression intercept and slope utilised to predict number of days pyrexic. Individual data points show mean average number of days pyrexic for each challenge dose group as recorded between Days 28 and 70. MLV = modified-live virus; PRRS = porcine reproductive and respiratory syndrome; TCID50 = 50% tissue culture infectious dose.
Table 3.
ADWG by treatment group and challenge dose.
Fig 3.
Estimated ADWG by challenge dose based on model prediction.
Regression intercept and slope utilised to predict ADWG. Individual data points show mean ADWG for each challenge dose group as recorded between Days 28 and 70. ADWG = average daily weight gain; MLV = modified-live virus; PRRS = porcine reproductive and respiratory syndrome; TCID50 = 50% tissue culture infectious dose.
Table 4.
Average number of days pigs showed any clinical signs, by treatment group and challenge dose.